101 related articles for article (PubMed ID: 18398612)
1. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
Erlich RB; Rickwood D; Coman WB; Saunders NA; Guminski A
Cancer Chemother Pharmacol; 2009 Feb; 63(3):381-9. PubMed ID: 18398612
[TBL] [Abstract][Full Text] [Related]
2. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells.
Krishna S; Brown N; Faller DV; Spanjaard RA
Laryngoscope; 2002 Apr; 112(4):645-50. PubMed ID: 12150517
[TBL] [Abstract][Full Text] [Related]
6. Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation.
Záskodová D; Rezácová M; Vávrová J; Vokurková D; Tichy A
Ann N Y Acad Sci; 2006 Dec; 1091():385-98. PubMed ID: 17341630
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells.
Rossi MJ; Sundararaj K; Koybasi S; Phillips MS; Szulc ZM; Bielawska A; Day TA; Obeid LM; Hannun YA; Ogretmen B
Otolaryngol Head Neck Surg; 2005 Jan; 132(1):55-62. PubMed ID: 15632910
[TBL] [Abstract][Full Text] [Related]
8. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Gao D; Xia Q; Lv J; Zhang H
Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
[TBL] [Abstract][Full Text] [Related]
9. Antileukemic activity of the combination of ionizing radiation with valproic acid in promyelocytic leukemia cells HL-60.
Rezacova M; Zaskodova D; Vavrova J; Vokurkova D; Tichy A
Neoplasma; 2008; 55(6):519-25. PubMed ID: 18999881
[TBL] [Abstract][Full Text] [Related]
10. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Kanao K; Mikami S; Mizuno R; Shinojima T; Murai M; Oya M
J Urol; 2008 Sep; 180(3):1131-6. PubMed ID: 18639283
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
[TBL] [Abstract][Full Text] [Related]
12. 7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma.
Heiduschka G; Erovic BM; Vormittag L; Skoda C; Martinek H; Brunner M; Ehrenberger K; Thurnher D
Arch Otolaryngol Head Neck Surg; 2009 Mar; 135(3):261-7. PubMed ID: 19289704
[TBL] [Abstract][Full Text] [Related]
13. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
Friedman J; Nottingham L; Duggal P; Pernas FG; Yan B; Yang XP; Chen Z; Van Waes C
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6568-78. PubMed ID: 18006756
[TBL] [Abstract][Full Text] [Related]
14. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
[TBL] [Abstract][Full Text] [Related]
15. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review.
Ferguson PJ
J Otolaryngol; 1995 Aug; 24(4):242-52. PubMed ID: 8551538
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma.
Azizzadeh B; Yip HT; Blackwell KE; Horvath S; Calcaterra TC; Buga GM; Ignarro LJ; Wang MB
Laryngoscope; 2001 Nov; 111(11 Pt 1):1896-900. PubMed ID: 11801965
[TBL] [Abstract][Full Text] [Related]
19. Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in Vitro.
Erjala K; Pulkkinen J; Kulmala J; Alanen K; Grenman R
Anticancer Res; 2002; 22(6A):3135-42. PubMed ID: 12530056
[TBL] [Abstract][Full Text] [Related]
20. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin.
Jaglowski JR; Stack BC
Cancer Lett; 2006 Nov; 243(1):58-63. PubMed ID: 16412572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
